167869B6-9620-445E-BA77-B6F95A6463F5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 95.03942181340341
- age_years
- 35
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.502
- MYC_TARGETS_V2+0.448
- WNT_BETA_CATENIN_SIGNALING+0.440
- NOTCH_SIGNALING+0.383
- MITOTIC_SPINDLE+0.258
- DNA_REPAIR+0.226
- UNFOLDED_PROTEIN_RESPONSE+0.118
- PANCREAS_BETA_CELLS+0.106
- UV_RESPONSE_UP+0.079
- UV_RESPONSE_DN+0.071
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.455
- INFLAMMATORY_RESPONSE-0.453
- IL6_JAK_STAT3_SIGNALING-0.446
- TNFA_SIGNALING_VIA_NFKB-0.413
- INTERFERON_GAMMA_RESPONSE-0.405
- IL2_STAT5_SIGNALING-0.374
- COAGULATION-0.361
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.344
- COMPLEMENT-0.316
- INTERFERON_ALPHA_RESPONSE-0.292
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0D8C7EC1-9BFB-44A1-8AF8-05D2A6BBE0F9 | — | — | 0.918 |
| 2 | A0502383-3883-4EB4-A63B-5586891AD3FC | — | — | 0.868 |
| 3 | 6819D9DA-FE18-4584-8AF6-E53DD894852E | — | — | 0.856 |
| 4 | 9CC5EB30-A8C2-4FDF-8074-467AA98ED1CA | — | — | 0.853 |
| 5 | ERR2598195 | fetal | fetal | 0.851 |
| 6 | TCGA-BH-A0HL-01A-11R-A10U-07 | — | B | 0.846 |
| 7 | BS_P39SQPTS | Embryonal tumors | — | 0.834 |
| 8 | A548DB97-6D28-4DEA-8334-201093A67B1E | — | — | 0.828 |
| 9 | E3818BAA-BA28-4CE4-A745-BB3692883888 | — | — | 0.825 |
| 10 | SRR11296886 | — | — | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.502 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.448 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.440 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.383 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.258 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.226 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.118 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.106 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.079 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.071 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.062 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.054 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.052 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.048 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.044 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.043 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.034 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.026 | Inavolisib | — uncovered |
| PEROXISOME | 0.004 | Idelalisib | — uncovered |